Pharma Pulse 8/13/24: Effective eConsent Strategies, Trump Campaign Says It Was Hacked & more

Effective eConsent Strategies for Every Study: Utilizing the eConsent Fit-for-Purpose Study Framework

Designing eConsent for each study from a stakeholders’ value, not technology perspective.

Promising Therapeutic Areas for PDTs and Addressing Unmet Needs in Mental Health

Arwen Podesta, MD, details the therapeutic areas in which prescription digital therapeutics (PDTs) have been studied and show the most promise, as well as some of the unmet needs in patients with mental health conditions that PDTs may be able to address.

Trump Campaign Says It Was Hacked

GOP campaign alleges Iran could be responsible, saying documents were stolen by ‘foreign sources’.

Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults

Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating two doses of ABRYSVO vaccine in immunocompromised adults aged 18 and older at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).

Divya Yerraguntla on LinkedIn

Super excited to share my article published today in PharmaExec.

As the biotech industry looks toward 2025, companies must navigate a complex landscape marked by regulatory challenges, evolving funding trends, and technological advancements. Their strategies will drive innovation, ensure sustainability, and maintain competitiveness.

In this feature article, I discuss a few critical strategic imperatives for biotech firms in light of the latest market dynamics and investor behaviors.

Would love to hear any additional insights.

#biotech #pharmaexec #featurearticle #healthcare #2025

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs